AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04769479
Drug: acoramidis
RxNorm normalized name: Acoramidis
DrugBank: Acoramidis (DB17999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acoramidis
Trial: NCT05314621
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Flonase® Allergy Relief (nasal spray)
Trial: NCT05314621
Drug: Tears Naturale
RxNorm normalized name: Tears Naturale
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tears Naturale® II (eye drop)
Trial: NCT05534594
Drug: 18F-PSMA-1007
RxNorm normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As explained under 'Arms'.
Trial: NCT05415137
Drug: Efzofitimod 3 mg/kg
DrugBank: Efzofitimod (DB16453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EfzofitimodIV infusion every 4 weeks for a total of 12 doses
Trial: NCT05415137
Drug: Efzofitimod 5 mg/kg
DrugBank: Efzofitimod (DB16453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EfzofitimodIV infusion every 4 weeks for a total of 12 doses
Trial: NCT06780839
Drug: Ensartinib
RxNorm normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Ensartinib 225mg QD by MRD test guided, if MRD test shows negative, only ensartinib will be given. if MRD test turns from negative to posive, patients will receive step-up treatment, which is ensartibe plus platinum - based doublet chemotherapy no more than 4 cycles. If MRD test turns from posive to negative, only ensartinib will be given. if MRD test constantly shows positive, MDT will determine the next step ensartib-based therapy.
Trial: NCT04996160
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT04996160
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8 mg/m2/day divided BID, PO, NG, or IV
Trial: NCT04996160
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.3 mg/m2/dose, IV (preferred) or SC
Trial: NCT05281484
Drug: CNM-Au8
RxNorm normalized name: CNM-Au8
DrugBank: CNM-Au8 (DB17952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids).~Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to up to 0.5 mg/mL (500 ppm).
Trial: NCT05188508
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive pembrolizumab 200mg IV on day 1 (± 3days) of each cycle. Pembrolizumab will continue every 21 days (± 3 days) throughout the trial.
Trial: NCT05276063
Drug: Linsitinib
RxNorm normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication taken twice daily by mouth
Trial: NCT05663710
Drug: 177Lu girentuximab
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Girentuximab (DB05304)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT05663710
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT05663710
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT06512584
Drug: PJ009
RxNorm normalized name: Pralsetinib
DrugBank: Pralsetinib (DB15822)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: subcutaneous injections, 0.05 mg/kg once daily
Trial: NCT06358573
Drug: INT230-6
RxNorm normalized name: INT230-6 COMPONENT CISPLATIN
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate.~The IMP is without marketing authorization in Switzerland and anywhere in the world.
Trial: NCT04761302
Drug: Intravenous morphine and oral oxycodone
RxNorm normalized name: oxycodone and ibuprofen
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg per kg intravenous every 6 hours with an additional oral oxycodone combined with acetaminophen 2 tabs every 6 hours.
Trial: NCT05765344
Drug: Bulevirtide
RxNorm normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Administered via subcutaneous injections.
Trial: NCT06305416
Drug: Ranibizumab 10mg/ml Injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab 10mg/ml Injection (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
Trial: NCT06305416
Drug: Lucentis
RxNorm normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
Trial: NCT04709380
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib is a multi-targeted oral drug for the treatment of cancer.Treatment of inoperable advanced renal cell carcinoma ,inoperable or distant metastatic primary hepatocellular carcinoma and so on.
Trial: NCT05653258
Drug: Dasatinib 100 MG
RxNorm normalized name: dasatinib 100 MG
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg of dasatinib (D) daily for 3 consecutive days plus quercetin (Q) for the same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
Trial: NCT05653258
Drug: Quercetin 1000mg
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (Q) (4) 250 mg capsules daily (total 1000 mg daily) plus dasatinib (D) same 3 consecutive days, followed by a 25-day (+/- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.
Trial: NCT06126380
Drug: AT-1501
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg PO twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent
Trial: NCT06126380
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent
Trial: NCT04990128
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg (1 mL) triamcinolone and 4 cc of lidocaine 1% that will be injected into the hip.
Trial: NCT04887792
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
Trial: NCT06798038
Drug: alcohol neurolysis
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 Patients will be administered with 1.0ml of 70% alcohol per genicular nerve
Trial: NCT04995835
Drug: Cefiderocol
RxNorm normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
Trial: NCT04651088
Drug: Potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.
Trial: NCT04651088
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 650mg tabs. Take 3 tabs twice daily.
Trial: NCT04651088
Drug: Potassium Bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mEq tablets, one tablet twice daily
Trial: NCT05062785
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This will be given intranasally at differing doses depending on study day. A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin. Each volunteer will come for 5 visits.~On the first treatment day participants will receive placebo (sterile water) in each nostril followed by a 4-hour observation period. After this observation period participants will receive the initial dose of insulin squirted in each nostril followed by a a 4 hour observation period. Participants will have at least 7 days in between the other 4 visits. Subsequent visits will include increased doses of insulin (depending on how this is tolerated) and will take approximately 4 hours at these visits.
Trial: NCT06790342
Drug: Cystine
RxNorm normalized name: Cystine
DrugBank: Cystine (DB00138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used for smoking cessation and alcohol reduction
Trial: NCT06785285
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To compare the effects of fentanyl and dexmedetomidine when used as adjuvants to intrathecal bupivacaine in elective cesarean section, assessing their impact on the onset and duration of spinal anesthesia, quality of analgesia, hemodynamic stability, incidence of side effects, and neonatal outcomes
Trial: NCT06790732
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received sham PENG block (just 1mL saline).
Trial: NCT06790732
Drug: Bupivacaine + Dexamethasone
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received real PENG block (15 mL of bupivacaine 0.25% +0.2mg/mL dexamethasone).
Trial: NCT04943952
Drug: Asparaginase Erwinia Chrysanthemi (recombinant)
RxNorm normalized name: Asparaginase Erwinia chrysanthemi (recombinant)
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JZP458 via intramuscular injection.
Trial: NCT06789107
Drug: Blinatumomab 9ug
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Blinatumomab for Refractory/Active Systemic Lupus Erythematosus. Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
Trial: NCT06792474
Drug: Lidocaine in Saline
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion 1.5 mg/kg/hr
Trial: NCT06783764
Drug: bupivacaine 0.25 % injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection of 10 ml 0.25% bupivacaine between pectoralis major and minor muscles and 10 ml between the pectoralis minor and serratus anterior muscles) at the third or the fourth rib, then 10 ml between the internal inter-costal muscles and the transversus thoracic muscle
Trial: NCT06783764
Drug: bupivacaine 0.25 % injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 ml of 0.25% bupivacaine injected deep to the erector spinae muscle at the transverse process of the fifth thoracic vertebrae
Trial: NCT06783491
Drug: Mitomycin (MM)
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin 30mg/m2/4 litres of perfusion liquid (dextrose 1.5%). Single intraoperative dose.
Trial: NCT06787118
Drug: CBD oil
RxNorm normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD OIL 3000]
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive CBD-oral solution 2.5 mg/kg PO BID for a total of 12 weeks.
Trial: NCT05301660
Drug: Nicotine transdermal patch
RxNorm normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 mg / tablet, one tablet a day, attached to the patient's back for 8 weeks
Trial: NCT06791434
Drug: Fixed Dose Combination Etoshine MR tablets
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composition per tablet: Etoricoxib 60 mg + Thiocolchicoside 4 mg
Trial: NCT05318534
Drug: GL-0719
RxNorm normalized name: GL-0719
DrugBank: GL-0719 (DB18436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration route: intravenous infusion and subcutaneous injection
Trial: NCT06785987
Drug: Continuous Lidocaine Infusion
RxNorm normalized name: Ivy Dry Super Continuous Spray
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintained with sevoflurane and continuous lidocaine infusion under dosage: 1.5 mg/kg/hr
Trial: NCT06786468
Drug: Standard systemic treatment for advanced lung cancer
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic treatment for advanced lung cancer
Trial: NCT06785662
Drug: The budesonide nasal irrigation
RxNorm normalized name: budesonide Nasal Spray
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The participant in this group used a solution containing 1 milligram of budesonide mixed with 240 milliliters of normal saline in a squeeze bottle (Cleanoze®) for nasal irrigation. The procedure will be performed once daily while leaning slightly forward over a sink.
Trial: NCT06785662
Drug: The budesonide nasal spray
RxNorm normalized name: budesonide Nasal Spray
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The participants in this group used a nasal spray containing 64 micrograms of budesonide per spray, with two sprays per nostril administered twice daily (morning and evening).
Trial: NCT06467357
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care chemotherapy by intravenous infusion
Trial: NCT06467357
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care chemotherapy by intravenous infusion
Trial: NCT06467357
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard of care immunotherapy by intravenous infusion
Trial: NCT06467357
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Experimental therapy by intravenous infusion
Trial: NCT06467357
Drug: Rilvegostomig
RxNorm normalized name: Rilvegostomig
DrugBank: Rilvegostomig (DB18991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental therapy by intravenous infusion
Trial: NCT05768360
Drug: Savolitinib
RxNorm normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive single dose of oral film-coated tablet of Savolitinib A dose on Day 1 of Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Trial: NCT06318403
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive patches with identical labeling from our pharmacy, to be applied twice weekly. In the study group, these will contain 0.025 mg/day of estradiol. In the control group, these will be placebo. These will be applied twice weekly for three months beginning at the time of surgery and extending for three months after surgery.
Trial: NCT06100237
Drug: Teclistamab
RxNorm normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
Trial: NCT06100237
Drug: Talquetamab
RxNorm normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talquetamab will be administered per discretion of treating physician. Participants will receive the recommended dosage.
Trial: NCT06100237
Drug: Daratumumab SC
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab SC will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
Trial: NCT06782724
Drug: Psilocybin therapy
RxNorm normalized name: Monistat Simple Therapy
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin therapy consisting of three preparation, two dosing, and three integration sessions. All sessions will take place in a controlled, safety environment and supported by two study therapists
Trial: NCT04708418
Drug: VLP-encapsulated TLR9 Agonist CMP-001
RxNorm normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC or intratumorally
Trial: NCT05583526
Drug: Ritlecitinib
RxNorm normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg capsule
Trial: NCT06784570
Drug: levosemindan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In common practice the loading dose is omitted as it is associated with hypotension.9 Usual dose range: 0.05 to 0.2 microg/kg/min. Dose based on actual body weight up to a maximum of 120 kg.5 Commence infusion at 0.05 microg/kg/min. If the initial rate is tolerated, consider increasing the maintenance rate to 0.1 microg/kg/min after 60 minutes. If the patient remains haemodynamically stable, further increase the dose to 0.2 microg/kg/min for the remainder of the infusion.
Trial: NCT06791070
Drug: Disitamab Vedotin combined with Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disitamab Vedotin at a dosage of 2mg/kg and 3mg/kg of Toripalimab administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
Trial: NCT05768360
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects will receive single dose of oral uncoated tablet of Digoxin Dose B on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Trial: NCT05768360
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The subjects will receive single dose of oral film-coated tablet of Metformin Hydrochloride Dose D on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Trial: NCT06788470
Drug: MSC
RxNorm normalized name: adMSC
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratracheal administration of umbilical cord-derived mesenchymal stem cells (MSCs).
Trial: NCT06787885
Drug: Levofloxacin + cefipime
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 2
Trial: NCT05768360
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects will receive single dose of oral solution of Furosemide Dose C on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Trial: NCT06784193
Drug: OP-3136
RxNorm normalized name: OP-1
DrugBank: Eptotermin alfa (DB11631)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: OP-3136
Trial: NCT05568537
Drug: Pylarify Piflufolastat Flourine-18 (18F-DCFPyL)
RxNorm normalized name: PIFLUFOLASTAT F-18
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piflufolastat F18 will first be given intravenously over about 5 seconds.
Trial: NCT05734066
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
Trial: NCT06246916
Drug: fianlimab
RxNorm normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration every 3 weeks (Q3W) in combination with cemiplimab
Trial: NCT05096195
Drug: Denosumab 60 mg/ml
RxNorm normalized name: denosumab 60 MG/ML
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Details described in intervention arm/group description section.
Trial: NCT06246916
Drug: cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV administration Q3W in combination with fianlimab